A Real-Life Study Assessing Long-term (7-Year Follow-up) Efficacy And Safety Of Omalizumab In Patients With Moderate-Severe Allergic Asthma
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2017 New trial record
- 06 Mar 2017 Results assessing the long term (up to 7 years) effectiveness and safety of omalizumab in patients with moderate-severe allergic asthma, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.